Clinical Report: Metabolomic Profiles in Serum as Predictors of Clinical Outcomes

Overview

This study investigates the relationship between serum metabolomic profiles and clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients undergoing pembrolizumab and chemotherapy. Key findings suggest that specific metabolites, particularly branched-chain amino acids and lipids, are associated with disease progression and overall survival.

Background

Lung cancer is the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) comprising the majority of cases. The combination of pembrolizumab and platinum-based chemotherapy has become a standard treatment for advanced NSCLC, yet predicting patient response remains challenging. Metabolomics offers a novel approach to identify biomarkers that may improve treatment stratification and outcomes.

Data Highlights

Key Findings

• Lower serum levels of BCAAs (valine and isoleucine) are associated with disease progression.
• Distinct metabolomic signatures correlate with overall survival in NSCLC patients.
• Long-term survivors exhibit higher levels of lipids, including total phospholipids and sphingomyelin.
• Inflammatory markers such as glycoprotein acetyls are linked to higher mortality rates.
• A Random Forest model achieved high accuracy (AUC = 0.93) in predicting survival status based on metabolomic profiles.

Clinical Implications

The identification of specific serum metabolites as biomarkers may enhance the ability to predict disease progression and survival in NSCLC patients receiving pembrolizumab and chemotherapy. This approach could lead to more personalized treatment strategies and improved patient outcomes.

Conclusion

Serum metabolomic profiling presents a promising avenue for predicting clinical outcomes in advanced NSCLC, highlighting the potential for non-invasive biomarkers in oncology.

Related Resources & Content

1. The ASCO Post, Incremental Advances Demonstrated in Management of Locoregional Lung Cancer, 2011 -- Incremental Advances Demonstrated in Management of Locoregional Lung Cancer
2. The ASCO Post, Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?, 2025 -- Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?
3. The ASCO Post, Updated Analysis From KEYNOTE-189: Adding Pembrolizumab to Pemetrexed/Platinum for Nonsquamous NSCLC, 2020 -- Updated Analysis From KEYNOTE-189
4. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, ASCO Publications, 2026 -- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations
5. Frontiers, Serum Metabolomic Signatures Predict Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab plus Platinum-based Chemotherapy, 2026 -- Serum Metabolomic Signatures Predict Clinical Outcomes
6. The ASCO Post — Plasma-Based Tumor Mutational Burden May Predict Response to Immunotherapy in Patients With Metastatic NSCLC KEY POINTS
7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
8. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline | ASCO Publications
9. Frontiers | Serum Metabolomic Signatures Predict Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab plus Platinum-based Chemotherapy